Arctic Bioscience AS (OSL:ABS)
Norway · Delayed Price · Currency is NOK 3.770
+0.070 (1.89%)
Aug 1, 2025, 3:58 PM CET
Arctic Bioscience AS Company Description
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific.
The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis.
It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name.
Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.
Arctic Bioscience AS
| Country | Norway |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Christer Valderhaug |
Contact Details
Address: Industrivegen 42 Ørsta, 6155 Norway | |
| Phone | 47 95 29 33 84 |
| Website | arctic-bioscience.com |
Stock Details
| Ticker Symbol | ABS |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010859580 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christer L. Valderhaug | Chief Executive Officer |
| Harald Nordal M.B.A., M.Sc. | Co-Founder and Chairman |
| Hogne Hallaraker | Founder and Chief Scientific Officer |
| Jone R. Slinning | Chief Financial Officer |
| Per Christian Sæbo | Chief Operating Officer |
| Daniele Mancinelli | Chief Technical Officer |
| Steffen Erland Eidal | Senior Vice President of Sales and Marketing |
| Dr. Yuming Feng | Executive Vice President of Global Business Development |
| Dr. Runhild Gammelsaeter | Global Medical Director |
| Dr. Para Ghildyal-Palani | Regulatory Manager |